Myriad Genetics, Inc. (MYGN)
After hours:
| Previous Close | 20.93 |
| Open | 20.70 |
| Bid | 18.75 x 1100 |
| Ask | 20.93 x 800 |
| Day's Range | 19.72 - 20.70 |
| 52 Week Range | 15.38 - 28.45 |
| Volume | |
| Avg. Volume | 565,188 |
| Market Cap | 1.621B |
| Beta (5Y Monthly) | 1.71 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.11 |
| Earnings Date | Nov 01, 2022 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 19.75 |
- GlobeNewswire
Myriad Genetics to Present New Data at San Antonio Breast Cancer Symposium Showcasing Advancements in Breast Cancer Risk Assessment and Treatment
Spotlight discussion highlights how combined risk score may lead to improved breast cancer prevention and screening strategies. SALT LAKE CITY, Nov. 29, 2022 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc., (NASDAQ: MYGN) a leader in genetic testing and precision medicine, today announced multiple presentations of new data at the 2022 San Antonio Breast Cancer Symposium (SABCS), including a spotlight discussion on breast cancer risk prediction. “Genetic testing is an essential tool across the continuu
- GlobeNewswire
GeneSight Mental Health Monitor Reveals Gap on the Front Line of Mental Health Care
Survey finds primary care providers wish patients would raise mental health concerns so they can provide better overall careSALT LAKE CITY, Nov. 17, 2022 (GLOBE NEWSWIRE) -- More than 83% of primary care providers (PCPs) wish more of their patients would talk to them about mental health issues and concerns so they can provide better overall care, according to the latest GeneSight® Mental Health Monitor, a nationwide survey from Myriad Genetics, Inc. (NASDAQ: MYGN). Yet, results of the Spring 202
- Zacks
Myriad Genetics' (MYGN) UroSuite to Improve Tailored Treatment
Myriad Genetics' (MYGN) latest launch is expected to aid clinicians with access to tools that can assist them with turnaround times and report interpretation.
